Search results for "Anti-inflammatory agents"

showing 10 items of 576 documents

Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis

2020

Abstract Fingolimod is an approved treatment for relapsing–remitting multiple sclerosis (MS), and its properties in different pathways have raised interest in therapy research for other neurodegenerative diseases. Fingolimod is an agonist of sphingosine-1-phosphate (S1P) receptors. Its main pharmacologic effect is immunomodulation by lymphocyte homing, thereby reducing the numbers of T and B cells in circulation. Because of the ubiquitous expression of S1P receptors, other effects have also been described. Here, we review preclinical experiments evaluating the effects of treatment with fingolimod in neurodegenerative diseases other than MS, such as Alzheimer’s disease or epilepsy. Fingolimo…

AgonistSphingosine 1 Phosphate Receptor ModulatorsMultiple Sclerosismedicine.drug_classDrug Evaluation PreclinicalDiseaseReview ArticleRM1-950PharmacologyNeuroprotection03 medical and health sciencesEpilepsyMice0302 clinical medicineNeurotrophic factorsAlzheimer DiseasemedicineAnimalsHumansLymphocytes030304 developmental biologyPharmacology0303 health sciencesEpilepsyMicrogliabusiness.industryFingolimod HydrochlorideMultiple sclerosisAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseFingolimod3. Good healthRatsDisease Models Animalmedicine.anatomical_structureNeuroprotective AgentsTherapeutics. PharmacologyNervous System Diseasesbusiness030217 neurology & neurosurgerymedicine.drugDrugs in R&D
researchProduct

Nasal Cellularity in 183 Unselected Schoolchildren Aged 9 to 11 Years

2002

Objective. Although rhinitis is extremely frequent in children, methods for assessing the severity of nasal inflammation produce results with wide variability and hence weak clinical significance. We designed this epidemiologic investigation to define the clinical usefulness of assessing nasal cellularity in children. Methods. We studied 183 of 203 eligible unselected schoolchildren who were aged 9 to 11 years and whose parents gave informed consent and completed a questionnaire on the history of atopic and respiratory symptoms. In all children, nasal swabs were obtained from both nostrils and eluted in saline and slides were prepared from cytospin preparations for staining and white cell c…

Allergymedicine.medical_treatmentRespiratory Tract DiseasesAnti-Inflammatory AgentsMucous membrane of noseLeukocyte CountneutrophilsFlunisolideAnti-Inflammatory Agents; Reproducibility of Results; Fluocinolone Acetonide; Skin Tests; Humans; Rhinitis; Child; Biopsy Needle; Exudates and Transudates; Leukocyte Count; Base Sequence; Respiratory Tract Diseases; Neutrophils; Nitrogen Oxides; Administration Intranasal; Nasal Mucosa; Breath TestsChildRespiratory Tract DiseaseSalineRhinitiSkin Testnasal cellularityBiopsy NeedleNeutrophilschoolchildrenExudates and Transudatesrespiratory systemExudates and TransudateNasal decongestantAnti-Inflammatory AgentFluocinolone AcetonideBreath TestsNasal SwabNitrogen Oxidesmedicine.symptomHumanmedicine.drugmedicine.medical_specialtyReproducibility of ResultNitrogen OxiderhinitisInternal medicineotorhinolaryngologic diseasesmedicineHumansAdministration IntranasalSkin TestsBase Sequencebusiness.industrynasal cellularity; neutrophils; rhinitis; allergy; schoolchildrenReproducibility of Resultsallergymedicine.diseaseNeutrophiliaNasal MucosaPediatrics Perinatology and Child HealthImmunologyNasal administrationbusinessPediatrics
researchProduct

Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid

2015

Abstract The objective of this paper is to apply a previously developed semi-physiologic pharmacokinetic model implemented in NONMEM to simulate bioequivalence trials (BE) of acetyl salicylic acid (ASA) in order to validate the model performance against ASA human experimental data. ASA is a drug with first-pass hepatic and intestinal metabolism following Michaelis–Menten kinetics that leads to the formation of two main metabolites in two generations (first and second generation metabolites). The first aim was to adapt the semi-physiological model for ASA in NOMMEN using ASA pharmacokinetic parameters from literature, showing its sequential metabolism. The second aim was to validate this mod…

AnalyteChemistry PharmaceuticalMetaboliteCmaxPharmaceutical ScienceBioequivalencePharmacologyModels BiologicalBiomarkers PharmacologicalFirst pass effectchemistry.chemical_compoundPharmacokineticsIn vivoHumansMedicineComputer SimulationTissue DistributionBiotransformationChromatographyAspirinDose-Response Relationship Drugbusiness.industryHippuratesAnti-Inflammatory Agents Non-SteroidalNONMEMDrug LiberationTherapeutic EquivalencychemistryPharmacology ClinicalSalicylic AcidbusinessAlgorithmsSoftwareEuropean Journal of Pharmaceutical Sciences
researchProduct

Cyclooxygenase inhibitors – current status and future prospects

2001

Prostaglandins are formed from arachidonic acid by the action of cyclooxygenase and subsequent downstream synthetases. Two closely related forms of the cyclooxygenase have been identified which are now known as COX-1 and COX-2. Both isoenzymes transform arachidonic acid to prostaglandins, but differ in their distribution and their physiological roles. Meanwhile, the responsible genes and their regulation have been clarified. COX-1, the pre-dominantly constitutive form of the enzyme, is expressed throughout the body and performs a number of homeostatic functions such as maintaining normal gastric mucosa and influencing renal blood flow and platelet aggregation. In contrast, the inducible for…

AngiogenesisInflammationPharmacologyStructure-Activity Relationshipchemistry.chemical_compoundIndometacinDrug DiscoverymedicineAnimalsHumansCyclooxygenase InhibitorsPharmacologyMolecular StructurebiologyAnti-Inflammatory Agents Non-SteroidalOrganic ChemistryGeneral Medicinemedicine.diseasechemistryBiochemistryEnzyme inhibitorRheumatoid arthritisbiology.proteinArachidonic acidCyclooxygenasemedicine.symptomHomeostasisForecastingmedicine.drugEuropean Journal of Medicinal Chemistry
researchProduct

Anti-arthritic activity of a lipophilic woad (Isatis tinctoria) extract

2006

A dichloromethane extract of Isatis tinctoria was tested in the adjuvant-induced arthritis model in rats. The extract (150 mg/kg p. o.) leads to a significant reduction of paw oedema. Radiographic, histological and clinical assessment confirmed reduced damage of cartilage and signs of inflammatory response in comparison to untreated control. No significant differences were observed in the tissular levels of cyclooxygenases 1 and -2, and of inducible nitric oxide synthase in Isatis treated and untreated animals. High dose treatment with Isatis extract for two weeks did not result in macroscopic lesions of the gastric mucosa.

Anti-Inflammatory AgentsAdministration OralPharmaceutical ScienceArthritisPharmacognosyAnalytical Chemistrylaw.inventionArthritis RheumatoidMicelawDrug DiscoveryGastric mucosamedicineAnimalsEdemaIsatisPharmacologyDose-Response Relationship DrugbiologyTraditional medicinePlant Extractsbusiness.industryMacrophagesOrganic ChemistryIsatisbiology.organism_classificationmedicine.diseaseRatsIsatis tinctoriaRadiographyNitric oxide synthaseDose–response relationshipmedicine.anatomical_structureComplementary and alternative medicineRats Inbred Lewbiology.proteinMolecular MedicineFemalePhytotherapybusinessPhytotherapyPlanta Medica
researchProduct

Inducers of heme oxygenase-1.

2008

Heme oxygenase-1 (HO-1) is an inducible rate-limiting enzyme which catalyzes group heme into carbon monoxide, iron and bilirubin. In the recent years, HO-1 expression has been reported as an important protective endogenous mechanism against physical, chemical and biological stress. In this regard, induction of this enzyme has shown beneficial effects in several pathologic conditions, such as inflammatory processes, atherosclerosis, carcinogenesis, ischemia-reperfusion systems or degenerative diseases. Complex intracellular signalling cascades mediate the expression of HO-1 in response to external stimuli, Transcription factors, as nuclear factor E2-related factor-2, activator protein-1, and…

Anti-Inflammatory AgentsAntineoplastic AgentsApoptosisAntioxidantsCatalysischemistry.chemical_compoundDrug DiscoverymedicineAnimalsHumansEnzyme inducerHemeTranscription factorPharmacologybiologyActivator (genetics)KinaseUp-RegulationHeme oxygenaseBiochemistryMechanism of actionchemistryEnzyme Inductionbiology.proteinmedicine.symptomSignal transductionHeme Oxygenase-1Signal TransductionTranscription FactorsCurrent pharmaceutical design
researchProduct

Carbon Monoxide-Releasing Molecules: A Pharmacological Expedient to Counteract Inflammation

2008

Carbon monoxide (CO) mediates many of the biological effects that are attributed to heme oxygenase (HO), the enzyme responsible for CO production in mammals. Antioxidant and anti-inflammatory activities of HO-1, the inducible isoform of heme oxygenase, have been demonstrated in a variety of disease models and a therapeutic exploitation of this pathway is currently under scrutiny. In this context, the liberation of CO from CO-releasing molecules (CO-RMs) is extremely attractive as these compounds may form the basis of a new class of pharmaceuticals. Recent investigations indicate that HO-1 and CO modulate important processes in chronic inflammation; these include the control of immune respon…

Anti-Inflammatory AgentsContext (language use)InflammationOsteoarthritisPharmacologyRutheniumArthritis RheumatoidDegenerative diseaseImmune systemOsteoarthritisDrug DiscoveryOrganometallic CompoundsAnimalsHumansMedicineInflammationPharmacologyCarbon Monoxidebusiness.industrymedicine.diseaseCarbon monoxide-releasing moleculesHeme oxygenaseOxidative StressImmunologyMetalloproteasesCytokinesmedicine.symptomSignal transductionbusinessHeme Oxygenase-1Signal TransductionCurrent Pharmaceutical Design
researchProduct

p Natural polyphenols as anti-inflammatory agents p

2009

Celiac Disease is a worldwide spread condition affecting 1:100-1:200 individuals. It is a permanent food intolerance to ingested gluten in genetically predisposed subjects. In this review we analyze the biochemical markers of the disease going from laboratory findings to histology passing through genetics. Gluten intolerance is a unique model of autoimmune disease in which we can recognize the main environmental factor (gluten) and the more complex genetic background. In additional way, serological markers for monitoring the disease and a safe and effective therapy (gluten free diet) are also available. In deed the environmental factor such as gluten intake is necessary to trigger the disea…

Anti-Inflammatory AgentsDiseaseHuman leukocyte antigenProtein Serine-Threonine KinasesModels BiologicalAntioxidantsGeneral Biochemistry Genetics and Molecular BiologyPathogenesisPhenolsmedicineHumansFlavonoidsInflammationchemistry.chemical_classificationAutoimmune diseaseMolecular StructureGeneral Immunology and Microbiologybusiness.industryPolyphenolsnutritional and metabolic diseasesGluten intolerancemedicine.diseaseGlutendigestive system diseasesFood intolerancechemistryCyclooxygenase 2ImmunologyCyclooxygenase 1Gluten freebusinessFrontiers in Bioscience
researchProduct

Effect of selected triterpenoids on chronic dermal inflammation.

1997

The activity of four natural triterpenoids on a 12-O-tetradecanoylphorbol-13-acetate multiple-dose model of skin chronic inflammation was studied. Erythrodiol and ursolic acid were significantly effective. The most important features concerning structure-activity relationship and previous data on the effect of these triterpenoids on other inflammatory conditions are discussed.

Anti-Inflammatory AgentsDrug Evaluation PreclinicalInflammationPharmacologyDermatitis ContactDexamethasonechemistry.chemical_compoundMiceTriterpenoidDermisUrsolic acidTriterpeneEdemamedicineAnimalsOleanolic AcidBetulinic AcidDexamethasonePharmacologychemistry.chemical_classificationintegumentary systembusiness.industryTriterpenesmedicine.anatomical_structurechemistryImmunologyTetradecanoylphorbol AcetateFemalemedicine.symptombusinessPentacyclic Triterpenesmedicine.drugEuropean journal of pharmacology
researchProduct

4-dimethylamino-3′,4′-dimethoxychalcone downregulates iNOS expression and exerts anti-inflammatory effects

2001

Abstract Reactive oxygen and nitrogen species contribute to the pathophysiology of inflammatory conditions. We have studied the effects of a novel superoxide scavenger, 4-dimethylamino-3′,4′-dimethoxychalcone (CH11) in macrophages and in vivo. CH11 has been shown to inhibit the chemiluminescence induced by zymosan in mouse peritoneal macrophages and the cytotoxic effects of superoxide. In the same cells, the modulation by superoxide of nitric oxide (NO) production in response to zymosan was investigated. CH11 was more effective than the membrane-permeable scavenger Tiron for inhibition of inducible nitric oxide synthase (iNOS) protein expression and nitrite production. We have shown that CH…

Anti-Inflammatory AgentsNitric Oxide Synthase Type IIPharmacologyCarrageenanNitric OxideBiochemistryGene Expression Regulation EnzymologicNitric oxideMicechemistry.chemical_compoundChalconeChalconesSuperoxidesIn vivoPhysiology (medical)AnimalsEdemaEnzyme InhibitorsRespiratory BurstInflammationTironbiologySuperoxideZymosanZymosanFree Radical ScavengersNitric oxide synthaseOxidative StresschemistryBiochemistryEicosanoidLuminescent Measurements12-Dihydroxybenzene-35-Disulfonic Acid Disodium SaltMacrophages Peritonealbiology.proteinFemaleTumor necrosis factor alphaNitric Oxide SynthaseFree Radical Biology and Medicine
researchProduct